Yesterday, Rule Breakers pick InterMune
Many investors are excited about ITMN-191, a HCV protease inhibitor compound, due to its similarity to Vertex's
InterMune plans on presenting the first human efficacy data from a phase 1 trial of ITMN-191 in the second half of this year. Investors won't have to wait that long for more information about the market potential of ITMN-191, though. Vertex and Schering-Plough
Early stage drug development is strange in that good clinical trial data for its competitors can also be good news for InterMune, since success with Vertex's or Schering's compounds validate InterMune's drug target. The time to parse the data to see which compound has the best efficacy, safety, and dosing profile will come in the not-too-distant future once ITMN-191 human clinical study data starts to come out. Right now, though, InterMune shareholders should be rooting for positive data from Vertex and Schering over the weekend.
InterMune and Vertex Pharmaceuticals are Rule Breakers selections. Looking for more Foolish drug stock coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.
More from The Motley Fool
InterMune Inc. Shareholders Can Now Breathe Easier Thanks to Roche
Roche stuns Wall Street and investors by snatching up InterMune and its first-in-class lung disease drug. But, does this deal make sense?
3 Stocks to Get on Your Watchlist
A biotech with a newly approved drug, a potentially cheap banking giant, and a possibly overvalued clinical-stage biotech with a promising rare-disease drug are this week's must-watch stocks.
The 3 Biggest Biotech Wins of the Week
See who released the best clinical results during the week ending May 25.